Bionic periosteum with bone immune regulation function and preparation method and application thereof

By preparing an electrospun membrane scaffold loaded with Periostin, the problems of immune response and osteogenesis in bone defect repair were solved, achieving immunomodulation and osteopromoting effects in bone repair, and improving the efficiency and quality of bone defect repair.

CN117860968BActive Publication Date: 2026-11-10CHINESE PEOPLES LIBERATION ARMY ARMY SPECIAL MEDICAL CENTER
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410045867.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-12
Publication Date
2026-11-10
Estimated Expiration
2044-01-12

AI Technical Summary

Technical Problem

Existing bone defect repair techniques suffer from problems such as limited sources of bone, long treatment cycles, bone resorption and incomplete osteogenesis, and immune responses caused by biological scaffolds affect the repair effect.

Method used

A biomimetic periosteum was prepared by using superimposed outer and inner electrospun membranes with uniformly distributed nano-hydroxyapatite on the surface and loaded with extracellular matrix protein Periodin. The outer layer is highly oriented and the inner layer is randomly oriented, which realizes bone immune regulation and promotes bone function.

Benefits of technology

Bionic periosteum can effectively regulate macrophage polarization, promote osteogenic differentiation, improve bone repair, reduce immune response, and shorten the treatment cycle.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117860968B_ABST
    Figure CN117860968B_ABST
Patent Text Reader

Abstract

The application discloses a kind of bionic periosteum with bone immune regulation function, including superimposed outer electrospinning membrane and inner electrospinning membrane, and the surface and interior of outer electrospinning membrane and inner electrospinning membrane are evenly distributed with nano-hydroxyapatite, and extracellular matrix protein is loaded on nano-hydroxyapatite.The application also discloses the preparation method and application of the bionic periosteum with bone immune regulation function.The bionic periosteum provided by the application loads Periostin on the surface of functionalized nano-hydroxyapatite from the perspective of multidimensional bionics, then disperses f-nHA loaded with Periostin in type I collagen solution, and prepares nanofiber scaffold material with two different surface topologies of high orientation and random orientation by electrospinning technology.Finally, by the composite of two materials, a kind of bionic periosteum with outer high orientation structure (FSa) having immune regulation function and inner random orientation structure (FSr) having osteogenesis promoting effect is constructed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomaterials technology, specifically relating to a biomimetic periosteum with immunomodulatory function, its preparation method, and its application. Background Technology

[0002] Bone defects occur in a large number of people every year due to factors such as trauma, infection, and tumors. Although bone tissue has a strong regenerative and repair capacity, it cannot heal itself for large bone defects. Currently used bone defect repair techniques include the Ilizarov technique, vascularized fibular grafting, and autologous cancellous bone grafting. However, these surgical methods all have significant limitations, such as limited bone resources, long treatment cycles, and the risk of graft resorption and incomplete osteogenesis. Therefore, researching ideal bone repair materials and treatment measures is of great significance for reducing disability rates and improving patients' quality of life.

[0003] Periosteum loss is a significant reason for poor osteogenic repair outcomes in bone grafts. However, using periosteal-like tissue to cover the surface of the graft material can mimic the periosteal-induced healing process. The rapid development of tissue engineering has provided new directions for the effective repair of bone defects. Biodegradable membranes made from natural / synthetic polymers are used, and the independent space created by the membrane material guides osteogenic cells to attach, proliferate, and differentiate into osteoblasts on its surface, thereby achieving bone regeneration.

[0004] After a biological scaffold is implanted into the host, the resulting immune response due to the foreign body reaction is often overlooked. An increase in the proportion of M1 macrophages or a prolonged period of M1 macrophage activity can lead to delayed bone repair or nonunion. M2 macrophages promote the differentiation of stem cells into osteoblasts and are beneficial for bone tissue repair and regeneration, especially in the later stages of inflammation, playing a crucial role in promoting mineralization. Implanting materials that promote M1 macrophage polarization can lead to the formation of granulomas and fibrous encapsulations around the graft, resulting in repair failure. In contrast, M2 macrophages can induce osteogenic differentiation of stem cells through the TGF-β1 pathway, participating in tissue repair. Therefore, M2 macrophages play a vital regulatory role in bone defect repair. Periostin, an extracellular matrix protein specifically expressed in the periosteum, can promote macrophage polarization towards the M2 type. Summary of the Invention

[0005] This invention aims to at least partially solve one of the technical problems in related technologies. Therefore, the main objective of this invention is to provide a biomimetic periosteum with bone immune-regulating function, its preparation method, and its applications.

[0006] The objective of this invention is achieved through the following technical solution:

[0007] In a first aspect, a biomimetic bone membrane with bone immune regulation function includes an outer electrospun membrane and an inner electrospun membrane stacked together, wherein nano-hydroxyapatite is uniformly distributed on the surface and inside of the outer electrospun membrane and the inner electrospun membrane, and the nano-hydroxyapatite is loaded with extracellular matrix proteins.

[0008] In some specific embodiments, both the outer electrospun membrane and the inner electrospun membrane are collagen fiber membranes, and the extracellular matrix protein is peristin.

[0009] In some specific embodiments, the outer electrospun membrane is composed of parallel-oriented nanofibers, and the inner electrospun membrane is composed of randomly oriented nanofibers.

[0010] Secondly, a method for preparing a biomimetic periosteum with bone immune-modulating function, comprising the following steps:

[0011] S1. Nano-hydroxyapatite was placed in a Periodin aqueous solution, allowed to stand at 2-6℃ for 3 days, and pf-nHA was obtained after precipitation and washing.

[0012] S2. A type I collagen solution was prepared using hexafluoroisopropanol as a solvent, and pf-nHA was dispersed in the type I collagen solution to obtain a collagen solution;

[0013] S3. Preparation of biomimetic periosteum: The collagen solution is electrospun at different rotation speeds to obtain an outer electrospun membrane of parallel-oriented nanofibers and an inner electrospun membrane of randomly oriented nanofibers.

[0014] S4. At least one outer electrospun membrane and at least one inner electrospun membrane are stacked together to prepare a biomimetic bone membrane.

[0015] In some specific embodiments, the nano-hydroxyapatite is obtained by the following preparation method:

[0016] 1) Precipitate and crystallize soluble calcium salt solution and phosphate solution under alkaline conditions, and after aging for 2-5 days, wash with deionized water until neutral to obtain nHA crystals;

[0017] 2) Prepare an nHA crystal solution by adding diphosphate dropwise to the nHA solution, stirring and reacting, centrifuging, removing the supernatant and washing with dH2O, and then redissolving with dH2O to obtain an alendronate sodium-modified nHA-AL solution.

[0018] 3) After adding the Fe3O4 suspension to the above nHA-AL solution and stirring to react, centrifuge, remove the supernatant and wash with dH2O to obtain f-nHA.

[0019] In some specific embodiments, the soluble calcium salt is Ca(NO3)2, the phosphate is (NH4)2HPO4 solution, the volume ratio of the soluble calcium salt solution to the phosphate solution is 1:(1-5), and the molar concentration of the soluble calcium salt solution is 0.3-0.6M, and the concentration of the phosphate solution is 0.5-0.5M; the bisphosphate is one or more of pamidronate sodium, alendronate sodium, and zoledronic acid sodium; the volume ratio of the bisphosphate solution to nHA crystals is 1:(1-3), the concentration of the nHA solution is 30-50mM, and the concentration of the bisphosphate solution is 6-10mM; the volume ratio of the nHA-AL solution to the Fe3O4 suspension is 1:(1-5), the concentration of the nHA-AL solution is 2-8mM, and the concentration of the Fe3O4 suspension is 3-8mM.

[0020] In some specific embodiments, the volume ratio of the f-nHA solution to the Periodin aqueous solution is 1:(2-6), the concentration of the f-nHA is 3-15 mM, the concentration of the Periodin aqueous solution is 40-60 μg / mL, the mass concentration of the type I collagen solution is 4-8%, and the mass concentration of the pf-nHA in the type I collagen solution is 3-8 mg / mL.

[0021] In some specific embodiments, the electrospinning parameters are: temperature 20-60℃, humidity 40-90%, electrostatic high voltage 5-20kV, receiving distance 5-20cm, injection rate 0.8-10mL / h, and the rotation speed of the receiving rod is set to either 300rpm or 50rpm.

[0022] In some specific embodiments, step S4 specifically involves: uniformly pouring a 2% collagen solution onto the surfaces of FSa and FSR of equal size, then pressing them together to form a composite membrane, freezing the composite membrane at -30 to -80°C for 12 to 36 hours, and then washing it with glutaraldehyde crosslinking followed by dH2O to obtain the biomimetic bone membrane.

[0023] Thirdly, the aforementioned biomimetic periosteum with bone immune regulation function, or the biomimetic periosteum with bone immune regulation function prepared by the aforementioned preparation method, is used in the preparation of bone repair products.

[0024] Compared with the prior art, the present invention has at least the following advantages:

[0025] The biomimetic periosteum provided by this invention, from a multidimensional biomimetic perspective, loads Periodin onto the surface of functionalized nano-hydroxyapatite (f-nHA), giving it not only the function of regulating macrophage M2 polarization but also the special functions of functionalized nano-hydroxyapatite such as promoting osteogenic differentiation and magnetic response. Then, the Periodin-loaded f-nHA (pf-nHA) is dispersed in a type I collagen solution, and two scaffold materials with different surface topologies—highly oriented (Fiber scaffold with Aligned Orientation, FSa) and randomly oriented (Fiber scaffold with Random Orientation, FSR)—are prepared using electrospinning technology. Finally, a biomimetic periosteum with bone immunomodulatory function is constructed by combining the two materials, so that the outer highly oriented structure has immunomodulatory function, and the inner randomly oriented structure promotes osteogenic function. Attached Figure Description

[0026] To more clearly illustrate the specific embodiments of the present invention, the accompanying drawings used in the description of the specific embodiments or the prior art will be briefly introduced below.

[0027] Figure 1 This is a flowchart illustrating the preparation process of pf-nHA in Example 1 of the present invention;

[0028] Figure 2 This is a flowchart illustrating the preparation process of the biomimetic periosteum in Embodiment 2 of the present invention;

[0029] Figure 3 The images show the morphological features of FSa, FSR, and FSa in Embodiment 2 of the present invention, including the surface structure of the inner electrospun membrane (FSr) of the biomimetic periosteum (1A) and the surface structure of the outer electrospun membrane (FSa) (1B); and the distribution of pf-nHA in the nanofiber scaffold (1C).

[0030] Figure 4 This diagram illustrates the effect of FSa and FSR of the biomimetic periosteum provided by this invention on macrophage polarization.

[0031] Figure 5 The diagram shows the effect of the fiber orientation of the biomimetic periosteum provided by this invention on osteogenic differentiation of PSCs.

[0032] Figure 6 HE staining image of newly formed tissue during bone regeneration of the biomimetic periosteum provided by this invention. Detailed Implementation

[0033] The present invention will be further described in detail below with reference to the accompanying drawings and embodiments. The following embodiments are merely descriptive and not limiting, and should not be construed as limiting the scope of protection of the present invention.

[0034] When a quantity, concentration, or other value or parameter is described as a range, preferred range, or preferred upper and lower limits, it should be understood that it is equivalent to specifically disclosing any range by combining any pair of upper or preferred values ​​with any lower or preferred values, regardless of whether the range is specifically disclosed. Unless otherwise stated, the numerical range values ​​listed herein include the endpoints of the range and all integers and fractions within that range.

[0035] Unless otherwise stated, all percentages, parts, ratios, etc. in this document are by weight.

[0036] The materials, methods, and embodiments described herein are exemplary and should not be construed as limiting unless otherwise stated.

[0037] Periostin was purchased from R&D Systems, alendronate sodium was purchased from aladdin, and other reagents were purchased from Sigma. Unless otherwise specified in the following examples, all raw materials can be obtained through existing commercial channels. The test methods or experimental methods can be the ones recommended by the vendors or conventional test methods or experimental methods in the field.

[0038] Example 1: Preparation of Periostin-loaded nano-hydroxyapatite (pf-nHA)

[0039] This embodiment provides a method for preparing periodin-loaded nano-hydroxyapatite, the preparation process of which is as follows: Figure 1 As shown, the specific steps include the following:

[0040] 1) Precipitate and crystallize 100 mL of soluble calcium salt Ca(NO3)2 (0.5 M) and 100 mL of phosphate (NH4)2HPO4 (0.3 M) solution in an alkaline environment (pH = 10-14). After aging for 3 days, wash with deionized water until neutral to obtain nHA crystals.

[0041] 2) To prepare a 40 mM nHA crystal solution, add 8 mM sodium alendronate (10 mL) dropwise to 10 mL of nHA (40 mM) solution, stir at 400 rpm and 37 °C for 16 h, centrifuge at 6000 rpm for 3 min, remove the supernatant and wash 6 times with dH2O, then redissolve in dH2O to 5 mM to obtain sodium alendronate-modified nHA solution (abbreviated as nHA-AL solution);

[0042] 3) An equal volume of 5 mM Fe3O4 suspension was added dropwise to the nHA-AL solution. The mixture was stirred at 400 rpm and 37°C for 3 h, then centrifuged at 6000 rpm for 3 min. The supernatant was removed and the mixture was washed 6 times with dH2O to obtain f-nHA.

[0043] 4) Prepare a 10 mM f-nHA solution. Place 10 mL of f-nHA solution (10 mM) in 10 mL of 50 μg / mL Periodin aqueous solution, let stand at 4 °C for 3 days, and obtain Periodin-loaded nano-hydroxyapatite (abbreviated as pf-nHA) after precipitation and washing.

[0044] Example 2: Preparation of biomimetic periosteum

[0045] Based on Example 1, the preparation method of the biomimetic periosteum provided in this example has the following preparation process: Figure 2 As shown, the specific steps include the following:

[0046] 1) Preparation of collagen solution: Prepare a 4-8% (w / v) type I collagen solution using hexafluoroisopropanol as solvent, and disperse pf-nHA at 5 mg / mL in the type I collagen solution to obtain the collagen solution.

[0047] 2) Electrospinning the collagen solution

[0048] 21) Using electrospinning technology, the electrospinning parameters are: temperature 25℃, humidity 40%, electrostatic high voltage 19kV, receiving distance 15cm, injection rate 1mL / h, and the rotation speed of the receiving rod is set to 300rpm to prepare the outer electrospinned membrane of parallel oriented nanofibers (FSa).

[0049] 22) Electrospinning technology was used with the following electrospinning parameters: temperature 25℃, humidity 40%, electrostatic high voltage 19kV, receiving distance 15cm, injection rate 1mL / h, and the rotation speed of the receiving rod was set to 50rpm. Randomly oriented nanofiber inner layer electrospinned film (FSr) was prepared.

[0050] That is, by electrospinning, collagen solution is used to prepare nanofiber scaffolds with different orientations.

[0051] 3) Preparation of biomimetic periosteum

[0052] A 2% collagen solution (2 mL) was uniformly poured onto the surfaces of FSa and FSR of equal size (5 cm × 5 cm), and then pressed tightly together to form a composite membrane. The composite membrane was then frozen at -80°C for 24 h and washed with glutaraldehyde-crosslinked dH2O to obtain the biomimetic periosteum (FSar).

[0053] Test example:

[0054] This application also conducts performance tests on the prepared biomimetic periosteum with bone immune-modulating function (taking the biomimetic periosteum prepared in Example 2 as an example), specifically:

[0055] 1) Morphological analysis of biomimetic periosteum

[0056] This embodiment describes the electron microscopy scanning of the biomimetic periosteum prepared in this application, specifically as follows:

[0057] Scanning electron microscopy (SEM): A 10mm × 10mm sample was fixed on the stage with conductive adhesive, sputtered with gold for 20 seconds, and then its morphology was observed under a scanning electron microscope (SEM, Crossbeam 340, Zeiss) at 2kV. The results are as follows. Figure 3 As shown in Figure 1A, the surface structures of the inner electrospun membrane (FSr) and outer electrospun membrane (FSa) of the biomimetic periosteum are shown in Figure 1B. The distribution of pf-nHA in the nanofiber scaffold was observed by transmission electron microscopy (TEM, Tecnai G2 F30 S-TWIN) (1C). It can be seen from the figure that the fibers in the inner electrospun membrane (FSr) and outer electrospun membrane (FSa) of the biomimetic periosteum are uniform and smooth. The fibers in the inner electrospun membrane (FSr) are randomly distributed in orientation, while the fibers in the outer electrospun membrane (FSa) are almost parallel. That is, the fiber orientation in the outer electrospun membrane and the inner electrospun membrane are different. In addition, the distribution of pf-nHA in the biomimetic periosteum was observed by transmission electron microscopy, as shown in Figure 1C. pf-nHA was successfully and uniformly loaded into the nanofibers of the biomimetic periosteum.

[0058] 2) Effects of biomimetic periosteum on the expression of IL-1β and IL-10 in macrophages

[0059] This application uses ELISA to detect changes in the expression of IL-1β and IL-10 in macrophages by biomimetic periosteum (FSar). Specifically, RAW 264.7 was used, and 2×10⁻⁶ cells were analyzed. 4 cells / cm 2 Cells were inoculated onto FS surfaces and cultured in DMEM high-glucose complete medium. After cell adhesion, the medium was replaced with serum-free DMEM high-glucose medium, and the supernatant was collected after 24 hours. The release of IL-1β and IL-10 was measured using an IL-1β and IL-10 ELISA kit according to the instructions (ELISA, Cloud-Clone, Wuhan, China). Results are as follows... Figure 4As shown in the figure, the expression level of IL-1β in the FSa group was significantly lower than that in the FSR group, while the expression trend of IL-10 was exactly the opposite; indicating that FSa can promote the polarization of macrophages into M2 macrophages in vitro.

[0060] 3) The effect of biomimetic periosteum on osteogenic differentiation of periosteal stem cells

[0061] This application uses qRT-PCR to detect the effect of biomimetic periosteum on osteogenic differentiation of periosteal stem cells (PSCs). Specifically, the process involves: first, taking third-generation PSCs, and then... 3 cells / cm 2 After inoculating onto FS surfaces and culturing in DMEM / F12 complete medium for 7 days, 1 mL of TRIzol was added, and the mixture was repeatedly pipetted for 5 min before being transferred to EP tubes. RNA was then extracted, and its quality was assessed based on A260 / A230 values ​​(1.8–2.0) and A260 / A280 values ​​(2.0–2.4). Finally, cDNA was synthesized, mixed with primers, and analyzed. Using Gapdh as an internal control, the analysis was performed using 2... -ΔΔCT Calculate expression changes (2) -ΔΔCT The calculation follows standard formulas in this field, therefore they will not be detailed here. The results are as follows: Figure 5 As shown in the figure, after 7 days of culture in the culture medium, the mRNA expression level of osteogenic-related genes in the FSr group was significantly higher than that in the FSa group, indicating that FSr can promote osteogenic differentiation of PSCs in vitro. Furthermore, the change in the transcription level of osteogenic-related genes after 7 days of culture of PSCs on the biomimetic periosteum was statistically significant (p < 0.01).

[0062] 4) Bone regeneration capacity test of biomimetic periosteum

[0063] This application uses a rat femoral defect model to test the bone regeneration capacity of a biomimetic periosteum. Specifically, male SD rats were anesthetized, shaved, and disinfected. First, a circular defect with a diameter of 2.5 mm was created in the middle of the femur using a trephine. Then, the defect area was covered with sterile FSa, FSR, and FSar, while the control group had no covering. Finally, the wound was sutured.

[0064] Meanwhile, we used HE staining to observe the pathological changes in the femoral regeneration process of rats 6 weeks after surgery, and the results are as follows: Figure 4 As shown in the figure, mature lamellar bone structures can be observed in the FSa group, with a large amount of new bone formation and collagen deposition at the bone defect site, and a preliminary closed structure is formed at the defect site; a small amount of bone structure can be seen in the FSa group, but less than the new bone formation in the FSR group. In the control group (blank group), due to the lack of physical barrier at the defect site, connective tissue fills the bone defect site, and there is no obvious new bone formation.

[0065] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be covered within the scope of the claims and specification of the present invention.

Claims

1. A biomimetic periosteum with bone immune regulation function, characterized in that, The membrane comprises an outer electrospun membrane and an inner electrospun membrane stacked together. Nano-hydroxyapatite is uniformly distributed on the surface and interior of both the outer and inner electrospun membranes. Extracellular matrix proteins are loaded onto the nano-hydroxyapatite. The biomimetic bone membrane with bone immunomodulatory function is prepared by the following method: Step S1. Place nano-hydroxyapatite in a Periodin aqueous solution, let it stand at 2-6°C for 3 days, and obtain pf-nHA after precipitation and washing; Step S2. Prepare a type I collagen solution with hexafluoroisopropanol as solvent, and disperse pf-nHA in the type I collagen solution to obtain a collagen solution; Step S3. Preparation of biomimetic periosteum: The collagen solution is electrospun at different rotation speeds to obtain an outer electrospun membrane of parallel-oriented nanofibers and an inner electrospun membrane of randomly oriented nanofibers. Step S4. At least one outer electrospun membrane and at least one inner electrospun membrane are stacked together to prepare a biomimetic bone membrane; The nano-hydroxyapatite is obtained by the following preparation method: 1) Precipitate and crystallize soluble calcium salt solution and phosphate solution under alkaline conditions, and after aging for 2-5 days, wash with deionized water until neutral to obtain nHA crystals; 2) To prepare an nHA crystal solution, add the diphosphate solution dropwise to the nHA solution, stir and react, centrifuge, remove the supernatant and wash with dH2O, then redissolve with dH2O to obtain an alendronate sodium-modified nHA-AL solution. 3) After adding the Fe3O4 suspension to the above nHA-AL solution and stirring to react, centrifuge, remove the supernatant and wash with dH2O to obtain f-nHA; The soluble calcium salt solution is Ca(NO3)2, the phosphate solution is (NH4)2HPO4 solution, the volume ratio of the soluble calcium salt solution to the phosphate solution is 1:(1-5), and the molar concentration of the soluble calcium salt solution is 0.3-0.6M, and the concentration of the phosphate solution is 0.5-0.5M; the bisphosphonate solution is one or more of pamidronate sodium solution, alendronate sodium solution, and zoledronic acid sodium solution; the volume ratio of the bisphosphonate solution to the nHA solution is 1:(1-3), the concentration of the nHA solution is 30-50mM, and the concentration of the bisphosphonate solution is... The concentration of the nHA-AL solution is 6-10 mM; the volume ratio of the nHA-AL solution to the Fe3O4 suspension is 1:(1-5), the concentration of the nHA-AL solution is 2-8 mM, and the concentration of the Fe3O4 suspension is 3-8 mM; the volume ratio of f-nHA to Periostin aqueous solution is 1:(2-6), the concentration of the f-nHA aqueous solution is 3-15 mM, and the concentration of the Periostin aqueous solution is 40-60 μg / mL; the mass concentration of the type I collagen solution is 4-8%, and the mass concentration of pf-nHA in the type I collagen solution is 3-8 mg / mL.

2. The biomimetic periosteum with bone immune regulation function according to claim 1, characterized in that, Both the outer and inner electrospun membranes are collagen fiber membranes, and the extracellular matrix protein is peristin.

3. The biomimetic periosteum with bone immune regulation function according to claim 1, characterized in that, The outer electrospun membrane is composed of parallel-oriented nanofibers, while the inner electrospun membrane is composed of randomly oriented nanofibers.

4. The biomimetic periosteum with bone immune regulation function according to claim 1, characterized in that, The electrospinning parameters are as follows: temperature 20-60℃, humidity 40-90%, electrostatic high voltage 5-20 kV, receiving distance 5-20 cm, injection rate 0.8-10 mL / h, and the rotation speed of the receiving rod is set to either 300 rpm or 50 rpm.

5. The biomimetic periosteum with bone immune regulation function according to claim 1, characterized in that, Step S4 is as follows: 2% collagen solution is poured evenly onto the surfaces of FSa and FSR of equal size, and then pressed together to form a composite membrane. The composite membrane is then frozen at -30 to -80°C for 12-36 h and washed with glutaraldehyde crosslinking followed by dH2O to obtain the biomimetic bone membrane.

6. The use of the biomimetic periosteum with bone immune regulation function as described in any one of claims 1-5 in the preparation of bone repair products.

Citation Information

Patent Citations

  • Method and device for activating stem cells

    CA2741426A1

  • Method of treating wounds with penostin and / or CCN2

    WO2014008582A1